EntryPoint Capital LLC Grows Position in COMPASS Pathways plc (NASDAQ:CMPS)

EntryPoint Capital LLC boosted its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 55.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,519 shares of the company’s stock after purchasing an additional 23,311 shares during the period. EntryPoint Capital LLC owned approximately 0.10% of COMPASS Pathways worth $248,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Polar Asset Management Partners Inc. boosted its holdings in COMPASS Pathways by 83.3% in the third quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock valued at $3,576,000 after acquiring an additional 258,000 shares during the last quarter. Sio Capital Management LLC grew its holdings in shares of COMPASS Pathways by 211.7% during the 3rd quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock worth $5,762,000 after purchasing an additional 621,222 shares during the period. Walleye Capital LLC acquired a new stake in COMPASS Pathways during the 3rd quarter worth approximately $2,126,000. Geode Capital Management LLC raised its holdings in COMPASS Pathways by 160.3% in the third quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock valued at $266,000 after buying an additional 25,970 shares during the period. Finally, Hennion & Walsh Asset Management Inc. lifted its position in COMPASS Pathways by 18.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 174,921 shares of the company’s stock valued at $661,000 after buying an additional 26,787 shares in the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

Analyst Upgrades and Downgrades

CMPS has been the topic of several research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Stifel Nicolaus assumed coverage on COMPASS Pathways in a research note on Thursday, February 27th. They issued a “buy” rating and a $11.00 target price for the company. Canaccord Genuity Group decreased their price target on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research note on Friday. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $21.83.

COMPASS Pathways Trading Down 4.9 %

NASDAQ:CMPS opened at $2.94 on Friday. COMPASS Pathways plc has a 12-month low of $2.88 and a 12-month high of $10.31. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. The business has a 50 day simple moving average of $3.86 and a 200 day simple moving average of $4.73. The firm has a market capitalization of $272.46 million, a P/E ratio of -1.34 and a beta of 2.29.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Equities research analysts predict that COMPASS Pathways plc will post -2.33 EPS for the current year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.